Group One Trading, L.P. I Teos Therapeutics, Inc. Transaction History

Group One Trading, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$10.33 - $18.09 $170,393 - $298,394	16,495 Added 237.54%	23,439 $347,000
Q1 2024 May 10, 2024	SELL	$9.89 - $13.64 $779,173 - $1.07 Million	-78,784 Reduced 91.9%	6,944 $94,000
Q4 2023 Feb 14, 2024	BUY	$8.57 - $11.06 $734,688 - $948,151	85,728 New	85,728 $938,000
Q2 2023 Aug 09, 2023	SELL	$12.93 - $18.05 $82,208 - $114,761	-6,358 Reduced 46.48%	7,321 $96,000
Q1 2023 May 12, 2023	BUY	$13.02 - $22.62 $178,100 - $309,418	13,679 New	13,679 $186,000
Q2 2022 Aug 11, 2022	BUY	$16.57 - $35.1 $91,135 - $193,050	5,500 New	5,500 $113,000

165

36.6M

1.95M

374K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $293M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.